JP2015501147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501147A5 JP2015501147A5 JP2014535807A JP2014535807A JP2015501147A5 JP 2015501147 A5 JP2015501147 A5 JP 2015501147A5 JP 2014535807 A JP2014535807 A JP 2014535807A JP 2014535807 A JP2014535807 A JP 2014535807A JP 2015501147 A5 JP2015501147 A5 JP 2015501147A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- comprises seq
- loop
- loop comprises
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010029697 CD40 Ligand Proteins 0.000 claims description 19
- 102100032937 CD40 ligand Human genes 0.000 claims description 19
- 102000008100 Human Serum Albumin Human genes 0.000 claims 12
- 108091006905 Human Serum Albumin Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 7
- 239000000178 monomer Substances 0.000 claims 7
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 101150013553 CD40 gene Proteins 0.000 claims 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008685 Chondritis Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 206010018498 Goitre Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229920000592 inorganic polymer Polymers 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546028P | 2011-10-11 | 2011-10-11 | |
| US61/546,028 | 2011-10-11 | ||
| PCT/US2012/059477 WO2013055745A2 (en) | 2011-10-11 | 2012-10-10 | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017090963A Division JP6539300B2 (ja) | 2011-10-11 | 2017-05-01 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501147A JP2015501147A (ja) | 2015-01-15 |
| JP2015501147A5 true JP2015501147A5 (enExample) | 2015-12-10 |
| JP6140712B2 JP6140712B2 (ja) | 2017-05-31 |
Family
ID=48082729
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535807A Active JP6140712B2 (ja) | 2011-10-11 | 2012-10-10 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
| JP2017090963A Active JP6539300B2 (ja) | 2011-10-11 | 2017-05-01 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
| JP2019106642A Active JP7068231B2 (ja) | 2011-10-11 | 2019-06-07 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
| JP2022073975A Active JP7560507B2 (ja) | 2011-10-11 | 2022-04-28 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
| JP2024161632A Pending JP2025000710A (ja) | 2011-10-11 | 2024-09-19 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017090963A Active JP6539300B2 (ja) | 2011-10-11 | 2017-05-01 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
| JP2019106642A Active JP7068231B2 (ja) | 2011-10-11 | 2019-06-07 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
| JP2022073975A Active JP7560507B2 (ja) | 2011-10-11 | 2022-04-28 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
| JP2024161632A Pending JP2025000710A (ja) | 2011-10-11 | 2024-09-19 | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10000553B2 (enExample) |
| EP (2) | EP2771022B1 (enExample) |
| JP (5) | JP6140712B2 (enExample) |
| KR (4) | KR102434073B1 (enExample) |
| CN (3) | CN103874501B (enExample) |
| AU (1) | AU2012323316B2 (enExample) |
| BR (1) | BR112014008804A2 (enExample) |
| CA (1) | CA2851667A1 (enExample) |
| CY (1) | CY1123690T1 (enExample) |
| DK (1) | DK2771022T3 (enExample) |
| ES (1) | ES2819075T3 (enExample) |
| HR (1) | HRP20201513T1 (enExample) |
| HU (1) | HUE051439T2 (enExample) |
| LT (1) | LT2771022T (enExample) |
| MX (2) | MX367013B (enExample) |
| PT (1) | PT2771022T (enExample) |
| RS (1) | RS60828B1 (enExample) |
| RU (1) | RU2704992C2 (enExample) |
| SG (2) | SG11201400567QA (enExample) |
| SI (1) | SI2771022T1 (enExample) |
| SM (1) | SMT202000513T1 (enExample) |
| WO (1) | WO2013055745A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009059298A2 (en) * | 2007-11-01 | 2009-05-07 | Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancinc immune responses to eimeria |
| KR102434073B1 (ko) | 2011-10-11 | 2022-08-18 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| RS62003B2 (sr) | 2014-11-10 | 2025-01-31 | Medimmune Ltd | Vezujući molekuli specifični za cd73 i njihove upotrebe |
| JP6862348B2 (ja) | 2015-03-12 | 2021-04-21 | メディミューン，エルエルシー | アルブミン融合タンパク質を精製する方法 |
| KR101810778B1 (ko) * | 2015-06-23 | 2017-12-20 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
| MY188405A (en) | 2015-08-05 | 2021-12-08 | Janssen Biotech Inc | Anti-cd154 antibodies and methods of using them |
| CA3052084A1 (en) * | 2017-01-09 | 2018-07-12 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| US11905313B2 (en) * | 2017-11-28 | 2024-02-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services. | Recombinant RSV G proteins and their use |
| WO2020068723A1 (en) * | 2018-09-24 | 2020-04-02 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| KR102919125B1 (ko) * | 2018-09-26 | 2026-01-27 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
| US12247320B2 (en) | 2018-10-24 | 2025-03-11 | Brandeis University | Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128 |
| US11447551B2 (en) | 2018-12-28 | 2022-09-20 | Sparx Bioscience Limited | Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases |
| CN111440253B (zh) * | 2019-01-17 | 2021-08-27 | 中国科学院上海药物研究所 | 立方形环糊精骨架-rgd组合物及其制备方法 |
| CA3219742A1 (en) * | 2021-05-21 | 2022-11-24 | Gabor Illei | Cd40l antagonist and uses thereof in the treatment of lupus nephritis |
| MX2024003985A (es) * | 2021-09-28 | 2024-04-29 | Viela Bio Inc | Andamios derivados de tn3 especificos para cd40l para su uso en el tratamiento y prevencion de la artritis reumatoide. |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| EP4703385A1 (en) | 2023-04-28 | 2026-03-04 | Fortvita Biologics Inc. | Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| CA2079802C (en) | 1990-04-05 | 2001-09-18 | Roberto Crea | Walk-through mutagenesis |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5440018A (en) | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| EP0781297A4 (en) | 1994-09-16 | 1999-05-19 | Scripps Research Inst | CYTOTACTIN DERIVATIVES THAT PROMOTE NEURONAL CONNECTIONS AND NEURITE GROWTH AND PROCESS YOUR PRODUCTION AND APPLICATION |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| US6160089A (en) | 1998-07-08 | 2000-12-12 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| CA2350417C (en) | 1998-12-02 | 2010-02-09 | Bristol-Myers Squibb Company | Dna-protein fusions and uses thereof |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2377468C (en) | 1999-07-27 | 2010-04-20 | Phylos, Inc. | Peptide acceptor ligation methods |
| US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| WO2003000856A2 (en) | 2001-06-21 | 2003-01-03 | Phylos, Inc. | In vitro protein interaction detection systems |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| DK2339016T3 (da) | 2002-03-29 | 2017-01-23 | Danisco Us Inc | Øget produktion af subtilisiner |
| WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
| WO2004001009A2 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
| KR100524872B1 (ko) | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| ATE528396T1 (de) | 2004-07-06 | 2011-10-15 | Bioren Inc | Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften |
| KR100852415B1 (ko) | 2004-07-13 | 2008-08-18 | 재단법인서울대학교산학협력재단 | 인간 테나신―ｃ 유래의 신규한 헤파린-결합부위를포함하는 폴리펩타이드 및 그의 유도체 |
| GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
| JP5027804B2 (ja) * | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス，インコーポレーテッド | ヒト化抗ｃｄ４０抗体およびその使用方法 |
| WO2007053661A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
| JP4959226B2 (ja) | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| JP5518702B2 (ja) | 2007-07-03 | 2014-06-11 | ダヌタ・クルセフスカ | α−ケトグルタレートの新規の医学的用途 |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2215246B1 (en) * | 2007-10-31 | 2015-01-07 | MedImmune, LLC | Protein scaffolds |
| AU2008345424A1 (en) * | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| CN102076713B (zh) | 2008-05-02 | 2015-03-25 | 诺华股份有限公司 | 改进的基于纤连蛋白的结合分子及其用途 |
| AR071874A1 (es) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| AU2009303526B2 (en) * | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| MX2011004550A (es) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos. |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| CN102596992B (zh) | 2009-02-12 | 2015-09-09 | 詹森生物科技公司 | 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途 |
| CN102549012B (zh) | 2009-05-07 | 2015-07-01 | 诺维信生物制药丹麦公司 | 纯化白蛋白的方法 |
| WO2011020033A2 (en) | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
| KR20130056870A (ko) | 2010-04-13 | 2013-05-30 | 메디뮨 엘엘씨 | 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드 |
| AU2011325134B2 (en) | 2010-11-05 | 2014-10-23 | Novartis Ag | Methods of treating rheumatoid arthritis using IL-17 antagonists |
| JP2014177354A (ja) | 2011-07-05 | 2014-09-25 | Asahi Glass Co Ltd | 窓ガラス |
| KR102434073B1 (ko) | 2011-10-11 | 2022-08-18 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| AU2015263285A1 (en) | 2014-05-19 | 2016-11-24 | Medimmune Limited | Treatment for rheumatoid arthritis |
| JP6862348B2 (ja) | 2015-03-12 | 2021-04-21 | メディミューン，エルエルシー | アルブミン融合タンパク質を精製する方法 |
| KR102919125B1 (ko) | 2018-09-26 | 2026-01-27 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
-
2012
- 2012-10-10 KR KR1020207019515A patent/KR102434073B1/ko active Active
- 2012-10-10 JP JP2014535807A patent/JP6140712B2/ja active Active
- 2012-10-10 BR BR112014008804A patent/BR112014008804A2/pt not_active Application Discontinuation
- 2012-10-10 SM SM20200513T patent/SMT202000513T1/it unknown
- 2012-10-10 RS RS20201146A patent/RS60828B1/sr unknown
- 2012-10-10 HU HUE12840074A patent/HUE051439T2/hu unknown
- 2012-10-10 MX MX2014004065A patent/MX367013B/es active IP Right Grant
- 2012-10-10 DK DK12840074.4T patent/DK2771022T3/da active
- 2012-10-10 SI SI201231843T patent/SI2771022T1/sl unknown
- 2012-10-10 EP EP12840074.4A patent/EP2771022B1/en active Active
- 2012-10-10 CN CN201280049742.2A patent/CN103874501B/zh active Active
- 2012-10-10 WO PCT/US2012/059477 patent/WO2013055745A2/en not_active Ceased
- 2012-10-10 HR HRP20201513TT patent/HRP20201513T1/hr unknown
- 2012-10-10 KR KR1020247031456A patent/KR20240142616A/ko active Pending
- 2012-10-10 KR KR1020147012468A patent/KR102132997B1/ko active Active
- 2012-10-10 PT PT128400744T patent/PT2771022T/pt unknown
- 2012-10-10 EP EP20177799.2A patent/EP3753567A1/en active Pending
- 2012-10-10 SG SG11201400567QA patent/SG11201400567QA/en unknown
- 2012-10-10 AU AU2012323316A patent/AU2012323316B2/en active Active
- 2012-10-10 CN CN201810653215.1A patent/CN108948196B/zh active Active
- 2012-10-10 CA CA2851667A patent/CA2851667A1/en active Pending
- 2012-10-10 CN CN202211152182.5A patent/CN116063509A/zh active Pending
- 2012-10-10 LT LTEP12840074.4T patent/LT2771022T/lt unknown
- 2012-10-10 ES ES12840074T patent/ES2819075T3/es active Active
- 2012-10-10 RU RU2014117511A patent/RU2704992C2/ru active
- 2012-10-10 KR KR1020227028109A patent/KR20220116585A/ko not_active Ceased
- 2012-10-10 SG SG10201707813YA patent/SG10201707813YA/en unknown
- 2012-10-10 US US14/347,016 patent/US10000553B2/en active Active
-
2014
- 2014-04-03 MX MX2019009104A patent/MX2019009104A/es unknown
-
2017
- 2017-05-01 JP JP2017090963A patent/JP6539300B2/ja active Active
-
2018
- 2018-05-31 US US15/993,964 patent/US11104720B2/en active Active
-
2019
- 2019-06-07 JP JP2019106642A patent/JP7068231B2/ja active Active
-
2020
- 2020-10-02 CY CY20201100927T patent/CY1123690T1/el unknown
-
2021
- 2021-07-28 US US17/387,269 patent/US11555062B2/en active Active
-
2022
- 2022-04-28 JP JP2022073975A patent/JP7560507B2/ja active Active
- 2022-11-01 US US18/051,704 patent/US20230242619A1/en active Pending
-
2024
- 2024-09-19 JP JP2024161632A patent/JP2025000710A/ja active Pending
-
2025
- 2025-01-16 US US19/025,394 patent/US20250257120A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014117511A (ru) | CD40L-СПЕЦИФИЧНЫЕ КАРКАСНЫЕ СТРУКТУРЫ, ПРОИСХОДЯЩИЕ ИЗ Tn3, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| CN113384693B (zh) | Fcrn抗体及其使用方法 | |
| ES2657304T3 (es) | Variantes de anticuerpo anti TFPI con unión diferencial a lo largo del intervalo de pH para mejorar la farmacocinética | |
| US9416182B2 (en) | Anti-TNF-anti-IL-17 bispecific antibodies | |
| JP2025000867A5 (enExample) | ||
| TWI651330B (zh) | 對ＦｃＲｎ具有專一性之抗體，其製造方法及用途 | |
| JP2014511844A5 (enExample) | ||
| JP2018500328A (ja) | 一本鎖Ｆｃ融合タンパク質 | |
| KR20140018299A (ko) | Ｔｎｆ-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법 | |
| RU2016135788A (ru) | Иммуноконъюгаты интерлейкина 10 | |
| JP2006249084A (ja) | 抗ＭａｄＣＡＭ抗体組成物 | |
| RU2016119755A (ru) | Стабильные водные составы на основе антител | |
| TW201538524A (zh) | 特異性結合人ｉｌ－１７ａ的分離的單克隆抗體 | |
| JP2013537416A5 (enExample) | ||
| BR122020023791B1 (pt) | Anticorpos anti-fcrn ou fragmentos de ligação-fcrn do mesmo, ensaio in vitro e composição farmacêutica | |
| ES2802982T3 (es) | Tratamiento de trastornos autoinmunitarios con anticuerpos contra CD154 | |
| CN108473571A (zh) | 结合人Fc受体的融合蛋白 | |
| TW202608919A (zh) | 白蛋白結合蛋白及使用方法 | |
| US12466877B2 (en) | Metallothionein antibodies and their use | |
| JP2021075580A5 (enExample) | ||
| TW202608916A (zh) | 白蛋白結合蛋白及使用方法 | |
| RU2024125665A (ru) | Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения | |
| US20180291093A1 (en) | Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof | |
| JP2022060182A5 (enExample) |